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Abstract: The Bactigras
 paraffin tulle coated with chlorhexidine is normally used for the 
treatment of donor-site wounds in burn patients who received split-thickness skin grafts in 
several  centers.  It  has  some  disadvantages,  such  as  adhesion  to  wound  surfaces  and  
pain from the irritation caused by this dressing. The Telfa AMD
, a non-adherent wound 
dressing which consists of absorbent cotton fibers impregnated with polyhexamethylene 
biguanide enclosed in a sleeve of thermoplastic polymers, is a new option for donor-site 
wound care which causes less adherence to the wound. The purpose of this study was to 
compare clinical efficacy of these two dressings for the management of donor-site wounds. 
Thirty-two patients who received split-thickness skin grafts by donor site harvesting from 
the thigh were enrolled in this study and randomized into two groups receiving either the 
Bactigras
 or the Telfa AMD
 wound treatment. Re-epithelialization, pain, infection and 
cost-effectiveness analyses were compared between both groups. The results showed that 
there was no significant difference in age, area of donor sites or length of hospital stays 
between  the  groups  (p  >  0.05).  However,  the  day  of  re-epithelialization  (≥90%)  was 
significantly shorter in patients treated with the Telfa AMD
 compared to the Bactigras
 
group  (14.00  ±  3.05  vs.  9.25  ±  1.88  days  for  Bactigras
  and  Telfa  AMD
  groups, 
respectively, p < 0.001). The average pain score was also significantly lower in the Telfa 
AMD
 group (1.57 ± 0.55 vs. 4.70 ± 1.16, p < 0.001). There was no difference in the cost 
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of  treatment  between  the  groups  (4.64  ±  1.97  vs.  5.72  ±  2.54  USD,  p  =  0.19).  This  
study  indicated  that  the  Telfa  AMD
  was  an  effective  dressing  for  the  treatment  of  
donor-site wounds. 
Keywords:  Bactigras;  burn;  chlorhexidine;  donor  site  wound;  polyhexamethylene 
biguanide; Telfa AMD 
 
1. Introduction 
Split-thickness  skin  grafting  is  the  most  frequently  used  procedure  in  plastic  surgery  for  the 
replacement  of  damaged  or  missing  skin.  The  success  of  the  procedure  depends  on  the  complete 
integration of the graft with the recipient bed and on the re-epithelialization of the skin graft donor  
site [1–3]. Treatment of the split-thickness autograft donor sites has been studied over the years but 
there is no standard treatment for managing these sites. The treatment protocol involves a variety of 
techniques and dressing materials, and all of them aim for a fast, spontaneous re-epithelialization of the 
donor  sites  [4].  Adequate  wound  treatment  aims  to  prevent  or  reduce  the  risk  of  associated 
complications and to facilitate the healing process whilst considering the patients’ physical and mental 
well-being during the treatment process [5]. The ideal treatment method protects the wounds from 
dehydration  and  mechanical  trauma,  prevents  infection  and  reduces  re-epithelialization  time,  and 
provides maximum comfort for the patient [6]. 
In  general,  the  methods  of  treating  donor  wounds  are  categorized  as  open,  semi-open,  and  
closed [7]. The open method refers to the method where the wound remains exposed and it is allowed 
to heal without a dressing. The semi-open method means the wound bed is covered with dressing just 
once and then the wound is allowed to heal by the open method while in the closed method, the wound 
dressing is left intact for two to seven days. The most common approach is to make multiple dressing 
changes until the wound is completely healed. Among these techniques, the closed methods meet these 
requirements for adequate wound treatment to a large extent and have become the most attractive 
technique over the last decade [8,9]. Paraffin gauze dressing is recognized as a standard treatment for 
split-thickness skin graft donor sites [10]. It is considered to be non-adherent; nevertheless, it usually 
sticks to the wound surface while it absorbs exudate. Early removal of the dressing may lead to skin 
maceration or wound infection and wound epithelialization may slough off, accompanied by local pain 
aggravation and wound deepening [11]. 
Chlorhexidine is an antibacterial agent which is effective against a wide range of Gram-positive and 
Gram-negative bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA). Traditionally, 
mesh  paraffin  gauze  with  chlorhexidine  is  normally  used  for  the  treatment  of  donor-site  wounds. 
Chlorhexidine  can  bind  to  bacterial  cell  walls  at  low  concentrations,  causing  an  alteration  of  the 
bacterial  cell  osmotic  equilibrium  and  leakage.  One  of  the  disadvantages  of  this  traditional  gauze 
includes adherence to wounds, which can cause trauma to epithelial cells when removed. The Telfa 
AMD
, a non-adherent wound dressing, consists of a thin layer of absorbent cotton fibers impregnated 
with polyhexamethylene biguanide (PHMB), enclosed in a sleeve of poly (ethylene terephthalate), a 
thermoplastic polymer, that is perforated in a regular pattern and sealed along two edges [12,13]. Int. J. Mol. Sci. 2011, 12                       
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Polyhexamethylene biguanide is a polymeric biguanide with a broad antimicrobial spectrum against 
both Gram-positive and Gram-negative bacteria, fungi and yeasts [14,15]. It has been used for several 
years as an antiseptic agent in medicine [16]. Polyhexamethylene biguanide binds to the surfaces of 
organisms causing instability and extensive disruption of their cytoplasmic membranes. It has a low 
systemic toxicity and poor absorption through skin. Since infection is another factor which retards 
wound healing, a broad spectrum antimicrobial agent may be beneficial for wound treatment as well as 
for split-thickness skin graft donor sites. 
The purpose of this study was to compare the clinical efficacy of the PHMB-containing wound 
dressing in the thermoplastic polymer with the paraffin tulle dressing coated with chlorhexidine, the 
standard treatment for skin graft donor sites in the management of donor-site wounds. 
2. Result and Discussion 
The alternative dressing materials used for split-thickness skin graft donor sites present differences 
in  healing  times,  infection  and  patient  comfort.  Since  all  of  the  dressings  possess  some  unique 
properties,  no  ideal  dressing  is  available  on  the  market  [17].  The  challenge  in  managing  donor  
site  wounds  is  to  promote  healing  as  quickly  as  possible  while  minimizing  adverse  effects  and 
complications [10]. If a complication such as infection occurs, the split-thickness defect may convert 
into  a  full-thickness  loss,  analogous  to  a  third-degree  burn  [10].  Because  of  this,  material  which 
contains antibacterial agents should be applied; however, it should not hinder wound healing and, in 
addition, it should preferably have a promoting effect on epidermal healing [18]. In contrast to the 
great number of studies in which different techniques for the dressing of donor sites were evaluated, 
our present study compared the efficacy of two occlusive dressings, the Bactigras
 dressing and the 
Telfa AMD
. The Bactigras
 dressing is commonly used as a standard protocol of donor site wound 
dressing  at  our  institute,  which  is  similar  to  many  burn  centers  using  paraffin  tulles  coated  with 
chlorhexidine  [10].  The  Telfa  AMD
  is  commercially  available  as  a  non-adherence  dressing  with 
antimicrobial agents, which may have advantages in terms of patient comfort.  
Thirty-two patients were enrolled in this study and all completed the follow-up period. Before the 
operation,  all  subjects  were  randomized  into  the  two  treatment  arms.  There  were  no  significant 
differences in demographic parameters between the two groups at baseline including age, area of donor 
site and length of hospital stay. However, there was a significant difference in gender between both 
groups (Table 1). During the study period, clinical observations showed that both dressings were easily 
applied and did not require special supplies. The adhesion of the Telfa AMD
 was lower than that of 
the Bactigras
 dressing, and after moisturizing the Telfa AMD
 was easily removed without damaging 
the newly formed epithelium. However, the Bactigras
 dressing had a greater level of adhesion to the 
wound surfaces, and there was a risk of damaging the delicate epithelium. Figure 1 shows the new 
donor sites to be treated with the Bactigras
 (Figure 1a) and Telfa AMD
 (Figure 1b) dressings.  Int. J. Mol. Sci. 2011, 12   
 
Table 1. Demographics da
Demographics Data  
Gender (male:female) 
Age (years) 
 
Area of donor sites (cm
2) 
 
Length of hospital stays (days) 
* indicates significant difference (
Figure 1. New donor sites treated with Bactigras
The donor sites treated with the Telfa AMD
of time taken for more than 90% re
of the patients in the Bactigras
 group (Table 2).
Table 2. Efficacy of Bactigras
 
Day of reepithelization (≥90%) 
 
Pain score 
 
Number of infection site 
Cost of treatment (USD) 
* indicates significant difference (
a 
            
Demographics data of patients in each group. 
Paraffin Tulle + 
Chlorhexidine Dressing 
(Bactigras
   ) 
(Range) 
Cotton Fiber + PHMB 
(Telfa AMD
(Range) 
 
14:2 
36.19 ± 19.81 
(16–78) 
1,016.38 ± 498.56 
(336–2,340) 
53.63 ± 36.22 
(9–126) 
8:8 
29.13 ± 12.55
(17–50) 
935.83 ± 436.47
(270–2,052)
47.69 ± 31.30
(13–124) 
* indicates significant difference (p < 0.05). 
New donor sites treated with Bactigras
 (a) and Telfa AMD
 (b
 
The donor sites treated with the Telfa AMD
 had a shorter re-epithelialization time and the length 
of time taken for more than 90% re-epithelialization was significantly different when compared to that 
group (Table 2). 
Efficacy of Bactigras
 and Telfa AMD
 in donor site wounds
Paraffin Tulle + 
Chlorhexidine Dressing 
(Bactigras
   ) 
(Range) 
Cotton Fiber + PHMB 
(Telfa AMD
(Range) 
14.00 ± 3.05 
(9–21) 
4.70 ± 1.16 
(2.20–6.64) 
1 
4.64 ± 1.97 
(2.12–9.55) 
9.25 ± 1.88
(7–13) 
1.57 ± 0.55
(0.57–2.57)
0 
5.72 ± 2.54
(1.73–12.09)
* indicates significant difference (p < 0.05). 
b 
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iber + PHMB 
(Telfa AMD
   ) 
 
p-Value 
29.13 ± 12.55 
 
935.83 ± 436.47 
2,052) 
47.69 ± 31.30 
 
0.02 * 
0.24 
 
0.63 
 
0.62 
b), respectively. 
 
epithelialization time and the length 
was significantly different when compared to that 
in donor site wounds. 
iber + PHMB 
Telfa AMD
   ) 
 
p-Value 
9.25 ± 1.88 
1.57 ± 0.55 
2.57) 
5.72 ± 2.54 
12.09) 
<0.001 * 
 
<0.001 * 
 
– 
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The  pain  assessment  also  showed  a  statistically  significant  difference  when  comparing  the 
applications of Telfa AMD
 and the  Bactigras
 dressing. The  average grade of pain in the Telfa 
AMD
 applications was much lower on all evaluation days (Table 3). However, the average grades of 
pain in both groups were within the ranges of discomfort and very slight pain, not within the range of 
real pain, which requires analgesia. 
Table 3. Average grade for the assessment of the pain in treatment with Bactigras
 and 
Telfa AMD
. 
Pain Score  Paraffin Tulle + 
Chlorhexidine 
Dressing (Bactigras
   ) 
(Range) 
Cotton Fiber + PHMB 
(Telfa AMD
   ) 
(Range) 
p-Value 
First day 
 
Third day 
 
Seventh day 
 
14
th–21
st day 
6.81 ± 1.17 
(5–9) 
6.38 ± 1.45 
(4–9) 
5.13 ± 2.03 
(0–8) 
1.88 ± 2.33 
(0–7) 
2.56 ± 1.41 
(0–5) 
1.88 ± 1.20 
(0–4) 
1.13 ± 1.15 
(0–4) 
0 
0 
<0.001 * 
 
<0.001 * 
 
<0.001 * 
 
<0.001 * 
 
* indicates significant difference (p < 0.05). 
Our results indicated that overall wound healing, as measured by the percentage of epithelialized 
dermis, was faster with the Telfa AMD
 than with the Bactigras
 dressing. The faster re-epithelialization 
rate  observed  with  the  Telfa  AMD
  can  partially  be  explained  by  its  physical  properties  since  it 
contains poly (ethylene terephthalate) polymers. Since the Telfa AMD
 has lower adhesion properties, 
it not only prevents trauma to the new and delicate epithelium during dressing removal, but it also 
provides  a  good  moist  environment,  which  is  preferred  for  epithelial  cell  proliferation  and  
migration  [19].  This  concept  was  well  supported  by  evidence  from  many  previous  studies  which 
showed  faster  re-epithelialization  rates  when  moist-environment  dressings  were  compared  with 
traditional dry dressings [7,19–21]. 
On the other hand, the Bactigras
 dressing has a greater absorptive effect, which resulted in a 
greater amount of adhesion. During dressing removal or patient movement, it is possible to damage the 
delicate  epithelial  cells  which  can  slow  wound  re-epithelialization  as  well  as  increase  patient 
discomfort. Therefore, the physical difference between these two dressings may be the reasons for our 
results.  Moreover,  a  case  of  Pseudomonas  aeruginosa  infection,  a  bacterium  which  is  of  especial 
concern in patients with burns, was found in a patient treated with the Bactigras
 dressing, which 
indicated that PHMB might be more beneficial in infection control than chlorhexidine. However, no 
mortality  or  any  side  effects  from  either  of  the  dressings  occurred  in  this  study.  With  respect  to 
bacterial growth, one patient in the Bactigras
 group was found to have a local infection on the tenth 
day  with  P.  aeruginosa  (10
2),  and  no  local  infection  was  observed  in  the  Telfa  AMD
  group. 
However, the microbial numbers were below the critical values. After receiving a standard systemic 
antibiotic, no isolated bacteria were found on the next day. Int. J. Mol. Sci. 2011, 12                       
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Pain is the main cause of patient discomfort which challenges burn treatment protocols. Our results 
indicated that the Telfa AMD
 results in statistically less pain at the donor site from the first day of 
treatment, and the pain score was significantly reduced after three days. Even though the pain score 
has completely subjective characteristics, it is a reflection of how comfortable patients feel during 
treatment and it has been widely used in similar studies. 
The results from the comparative cost-effective analysis showed that the cost difference between 
both dressings was insignificant. The total cost of patients treated with the Telfa AMD
 was slightly 
higher than the Bactigras
 dressing, which may have been due to the cost of the dressing itself.  
3. Experimental Section 
This was a prospective, randomized control study comprising 32 patients treated at the Siriraj Burn 
Unit,  Thailand  during  December  2008–February  2010.  It  was  designed  to  be  open-labeled  and 
observer blinded. The study was approved by Institutional Review Board Committee of the hospital, 
and written informed consent was obtained from each patient who enrolled in the study.  
Twenty-two of the patients were men and ten were women, aged 16–78 years old. All monitored 
patients had similar burns with regard to the burn area and the depth of donor sites. Patients who need 
skin graft operation were randomized by computer and placed into two groups: 16 donor sites were 
treated  with  the  Bactigras
  paraffin  tulle  dressing  coated  with  chlorhexidine  (Smith  &  Nephew 
Healthcare Limited, Hull, UK), and 16 donor sites were treated with the Telfa AMD
 cotton fiber 
impregnated with PHMB (Covidien, Mansfield, MA, USA). The demographic were collected from 
each subject in both group including age, gender, area of donor site (cm
2), operative time and length of 
hospital stay. 
The donor site was at the proximal thigh area. The patients were excluded if they were allergic to 
paraffin, chlorhexidine, poly (ethylene terephthalate) or PHMB. They were also excluded if there were 
lesions on both thighs, if they had psychiatric problems or multiple injuries (more than two systems 
involved), if they were immunocompromised, such as with renal failure, cirrhosis or malnutrition, and 
if  they  were  receiving  radiation  or  chemotherapy  for  malignancy.  Patients  with  diabetes  mellitus, 
systemic lupus erythematosus or other connective tissue diseases, and patients who had donor sites in 
areas other than the thigh were also excluded. Patients who did not comply with the study protocol, or 
who had a skin graft which had previously been harvested from the same donor site area, could not be 
involved in this study either.  
All of the skin grafts (0.010 inches thickness) were taken from the thigh using a Zimmer
 Air 
Dermatome Skin Grafting System (Zimmer, Ltd., Swindon, UK). The area of donor site (cm
2) was 
calculated using Image J Java-based image processing program developed by the National Institutes  
of  Heath.  Immediately  after  harvest,  the  donor  site  was  covered  with  a  saline-soaked  gauze  for 
hemostasis until surgery was completed. The Bactigras
 or Telfa AMD
 dressing were applied to the 
donor wound covering about 1 cm of intact skin. The dressing was secured by a sterile gauze. The 
donor site wounds were inspected every day after operation. None of the dressings were changed until 
the wounds were completely dry and the dressings fell off. 
A donor site follow-up chart was used to conduct the clinical follow-up of the healing process. The 
information gathered in the chart included the percentage of re-epithelialization of each donor site area, Int. J. Mol. Sci. 2011, 12                       
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the state of healthy skin on the periphery of each donor site and local signs of infection. Moreover, 
local pain was also followed-up using a visual analogue pain scale from 0 (no pain) to 10 (maximal 
severe pain) which was recorded at 30 minutes after the open wound, then at days 3, 7, 14 and 21 or 
when the dressing fell off. Normal saline solution was used to moisturize the dressing prior to removal 
and it is considered as neutral solution, no interaction has been found between normal saline and  
all dressing materials. The patients and the observer were blinded to the type of dressing in each  
donor site. 
Infection was also evaluated by swab cultures for a microbiological analysis which was performed 
routinely once a week on Tuesday. A cost-effectiveness analysis was also compared between these 
treatment groups. The costs of the dressings, supplies and nursing labor were used to calculate the 
treatment cost.  
Comparative  analyses  of  the  patients  in  both  groups  were  performed  using  two-tailed  unpaired 
student’s t-test with SPSS version 10.0 (SPSS Inc., Chicago, IL, USA). The results were expressed as 
mean (±SD). A p < 0.05 was considered as statistically significant. 
4. Conclusions  
Both the Bactigras
 dressing and the Telfa AMD
 are easy to apply in clinical practice. They can 
both protect wounds against mechanical trauma and provide comfort for the patients. However, the 
Telfa AMD
 provides a shorter re-epithelialization time, prevents infection and generates lower pain 
level in comparison with the Bactigras
 dressing. The treatment cost difference between these two 
dressings is negligible. 
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